MA56137A - Sels de valbénazine et leurs polymorphes - Google Patents

Sels de valbénazine et leurs polymorphes

Info

Publication number
MA56137A
MA56137A MA056137A MA56137A MA56137A MA 56137 A MA56137 A MA 56137A MA 056137 A MA056137 A MA 056137A MA 56137 A MA56137 A MA 56137A MA 56137 A MA56137 A MA 56137A
Authority
MA
Morocco
Prior art keywords
polymorphs
valbenazine salts
valbenazine
salts
Prior art date
Application number
MA056137A
Other languages
English (en)
Other versions
MA56137B1 (fr
Inventor
Thierry Bonnaud
Andrew Carr
Kevin Mcgee
Scott ZOOK
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57281297&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA56137(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of MA56137A publication Critical patent/MA56137A/fr
Publication of MA56137B1 publication Critical patent/MA56137B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA56137A 2015-10-30 2016-10-28 Sels de dihydrochlorure de valbénazine et leurs polymorphes MA56137B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562249074P 2015-10-30 2015-10-30
PCT/US2016/059306 WO2017075340A1 (fr) 2015-10-30 2016-10-28 Sels de valbénazine et polymorphes associés

Publications (2)

Publication Number Publication Date
MA56137A true MA56137A (fr) 2022-04-13
MA56137B1 MA56137B1 (fr) 2024-03-29

Family

ID=57281297

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43116A MA43116B1 (fr) 2015-10-30 2016-10-28 Ditosylate de valbénazine et polymorphes associés
MA56137A MA56137B1 (fr) 2015-10-30 2016-10-28 Sels de dihydrochlorure de valbénazine et leurs polymorphes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA43116A MA43116B1 (fr) 2015-10-30 2016-10-28 Ditosylate de valbénazine et polymorphes associés

Country Status (31)

Country Link
US (4) US10065952B2 (fr)
EP (3) EP4344742A3 (fr)
JP (2) JP7109360B2 (fr)
KR (1) KR20180075591A (fr)
CN (3) CN115304596A (fr)
AU (1) AU2016343633B2 (fr)
BR (1) BR112018008460A2 (fr)
CA (1) CA3002074A1 (fr)
CL (1) CL2018001089A1 (fr)
CO (1) CO2018004589A2 (fr)
CY (1) CY1124002T1 (fr)
DK (2) DK3368534T3 (fr)
EA (1) EA201890852A1 (fr)
ES (2) ES2857085T3 (fr)
FI (1) FI3875459T3 (fr)
HR (2) HRP20240304T1 (fr)
HU (2) HUE065406T2 (fr)
IL (2) IL284874B2 (fr)
LT (2) LT3368534T (fr)
MA (2) MA43116B1 (fr)
MX (1) MX2018005136A (fr)
MY (1) MY193767A (fr)
PH (1) PH12018500900A1 (fr)
PL (2) PL3368534T3 (fr)
PT (2) PT3368534T (fr)
RS (2) RS65154B1 (fr)
SA (1) SA518391477B1 (fr)
SG (1) SG11201803408PA (fr)
SI (2) SI3368534T1 (fr)
TN (1) TN2018000121A1 (fr)
WO (1) WO2017075340A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065406T2 (hu) 2015-10-30 2024-05-28 Neurocrine Biosciences Inc Valbenazin-dihidroklorid sók és polimorfjaik
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
KR20190062460A (ko) 2016-10-06 2019-06-05 아시아 케미컬 인더스트리스 리미티드 발베나진의 고체상 형태
WO2018102673A1 (fr) * 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Utilisation de valbénazine pour le traitement de la schizophrénie ou d'un trouble schizo-affectif
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
KR20230038601A (ko) 2017-01-27 2023-03-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 ｖｍａｔ2 억제제의 투여 방법
US10954235B2 (en) * 2017-02-27 2021-03-23 Sandoz Ag Crystalline forms of valbenazine salts
US20200179352A1 (en) * 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
CA3076000A1 (fr) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. Formulation de valbenazine a dosage eleve et compositions, procedes et kits associes
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US20200230127A1 (en) * 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
KR20200108828A (ko) 2017-11-22 2020-09-21 아시아 케미컬 인더스트리스 리미티드 발베나진의 고상 형태
KR102447769B1 (ko) * 2017-12-26 2022-09-26 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 발베나진 토실산염의 결정형 및 그 제조 방법 및 용도
CN110818705A (zh) * 2018-08-14 2020-02-21 苏州鹏旭医药科技有限公司 缬苯那嗪的盐型和相应晶型与其制备方法
EP3836926A4 (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. Procédés d'administration de certains inhibiteurs de vmat2
CA3065236A1 (fr) 2018-12-27 2020-06-27 Apotex Inc. Nouvelle forme cristalline de dibesylate de valbenazine
WO2020213014A1 (fr) 2019-04-19 2020-10-22 Mylan Laboratories Limited Procédé amélioré pour la préparation de valbénazine et de ses sels
US10689380B1 (en) * 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP2022547990A (ja) 2019-09-13 2022-11-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド バルベナジンの合成のための方法
CA3191084A1 (fr) * 2020-09-09 2022-03-17 Gerald Burke Formulations d'un modulateur de somatostatine
CA3215792A1 (fr) 2021-04-26 2022-11-03 John Lloyd Tucker Procedes de synthese de valbenazine
WO2023278991A1 (fr) * 2021-06-30 2023-01-05 Neurocrine Biosciences, Inc. Valbénazine destinée à être utilisée dans le traitement de la dyskinésie due à une paralysie cérébrale
MX2023014827A (es) 2021-06-30 2024-01-15 Neurocrine Biosciences Inc Valbenazina para usarse en el tratamiento complementario de la esquizofrenia.
IL310907A (en) 2021-08-20 2024-04-01 Neurocrine Biosciences Inc Screening methods for VMAT2 inhibitors

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5777697A (en) 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
JPS57209225A (en) 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (fr) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Formulation a liberation-retard
DK0839525T3 (da) 1996-10-31 2004-11-29 Takeda Pharmaceutical Præparat med forlænget frigivelse
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
WO1998027980A2 (fr) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Procede de production d'une preparation a liberation prolongee
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
AU1321900A (en) 1998-10-23 2000-05-15 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
AU2001276608A1 (en) 2000-08-30 2002-03-13 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
WO2003099011A1 (fr) 2002-05-28 2003-12-04 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Utilisation de glucosides cardiotoniques pour le traitement de la mucovicidose et autres troubles dependant de il-8
AU2003272608A1 (en) 2002-09-19 2004-04-08 University Of Utah Research Foundation Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2005117978A2 (fr) 2004-06-04 2005-12-15 Genentech, Inc. Methode de traitement de la sclerose en plaques
ES2318771T3 (es) 2005-08-06 2009-05-01 Cambridge Laboratories (Ireland) Limited 3,11b-cis-dihidrotetrabenazinas para el tratamiento de la esquizofrenia y otras psicosis.
US20100076087A1 (en) 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
CA2668689C (fr) * 2006-11-08 2015-12-29 Neurocrine Biosciences Inc. Composes 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol substitues et procedes associes
GB0721669D0 (en) 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
CA2711655C (fr) 2008-01-18 2013-03-05 Eisai R&D Management Co., Ltd. Derive d'aminodihydrothiazine condensee
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463452A (en) 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
US8524733B2 (en) 2008-09-18 2013-09-03 Auspex Pharmaceuticals Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20100096319A1 (en) 2008-10-17 2010-04-22 General Electric Company Separator assembly
EP2464340A2 (fr) 2009-08-12 2012-06-20 Valeant International (Barbados) SRL Compositions pharmaceutiques
US20120003330A1 (en) 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
BR112015005894B1 (pt) 2012-09-18 2022-03-29 Auspex Pharmaceuticals, Inc Composto, composição farmacêutica, método para tratar um distúrbio mediado por vmat2 e formulação farmacêutica de liberação prolongada
KR102148990B1 (ko) 2012-12-18 2020-08-27 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
EA201500801A1 (ru) 2013-01-31 2016-01-29 Ауспекс Фармацетикалс, Инк. Бензохинолоновые ингибиторы vmat2
WO2015077521A1 (fr) 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Inhibiteurs benzoquinoline du transporteur de monoamine vésiculaire 2
EP3099299A4 (fr) 2014-01-27 2017-10-04 Auspex Pharmaceuticals, Inc. Inhibiteurs de benzoquinoline du transporteur vésiculaire des monoamines 2
NZ760790A (en) 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
CA2938244A1 (fr) * 2014-02-07 2015-08-13 Auspex Pharamaceuticals, Inc. Nouvelles formulations pharmaceutiques
KR20160147044A (ko) * 2014-05-06 2016-12-21 뉴로크린 바이오사이언시즈 인코퍼레이티드 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
EP3253752B1 (fr) 2015-02-06 2023-08-16 Neurocrine Biosciences, Inc. [9,10-diméthoxy-3-(2-méthylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinéloin-2-yl]méthanol et composés, compositions et procédés associés
KR102528845B1 (ko) 2015-03-06 2023-05-08 오스펙스 파마슈티칼스, 인코포레이티드 비정상적 불수의 운동 장애의 치료 방법
US20190015396A1 (en) 2015-06-23 2019-01-17 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
HUE065406T2 (hu) 2015-10-30 2024-05-28 Neurocrine Biosciences Inc Valbenazin-dihidroklorid sók és polimorfjaik
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
WO2018102673A1 (fr) 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Utilisation de valbénazine pour le traitement de la schizophrénie ou d'un trouble schizo-affectif
KR20230038601A (ko) 2017-01-27 2023-03-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 ｖｍａｔ2 억제제의 투여 방법
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
CA3076000A1 (fr) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. Formulation de valbenazine a dosage eleve et compositions, procedes et kits associes
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
KR20210021006A (ko) 2018-06-14 2021-02-24 뉴로크린 바이오사이언시즈 인코퍼레이티드 Vmat2 억제제 화합물, 조성물 및 그와 관련된 방법
EP3836926A4 (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. Procédés d'administration de certains inhibiteurs de vmat2
US10689380B1 (en) * 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate

Also Published As

Publication number Publication date
CA3002074A1 (fr) 2017-05-04
EP3875459B1 (fr) 2023-12-13
SI3875459T1 (sl) 2024-06-28
HUE053872T2 (hu) 2021-07-28
ES2857085T3 (es) 2021-09-28
SG11201803408PA (en) 2018-05-30
CY1124002T1 (el) 2022-05-27
IL284874B2 (en) 2023-10-01
PT3875459T (pt) 2024-02-21
LT3368534T (lt) 2021-04-12
IL258732A (en) 2018-06-28
US20200339575A1 (en) 2020-10-29
HRP20240304T1 (hr) 2024-05-10
SI3368534T1 (sl) 2021-04-30
JP2018531963A (ja) 2018-11-01
CN108473489B (zh) 2022-09-02
US20170145008A1 (en) 2017-05-25
EP4344742A2 (fr) 2024-04-03
WO2017075340A1 (fr) 2017-05-04
EP4344742A3 (fr) 2024-06-26
PT3368534T (pt) 2021-03-09
MX2018005136A (es) 2018-05-07
IL284874B1 (en) 2023-06-01
FI3875459T3 (fi) 2024-02-14
RS61645B1 (sr) 2021-04-29
BR112018008460A2 (pt) 2018-11-06
SA518391477B1 (ar) 2022-03-20
US20200339576A1 (en) 2020-10-29
IL284874A (en) 2021-08-31
MA56137B1 (fr) 2024-03-29
CN108473489A (zh) 2018-08-31
EP3368534B1 (fr) 2021-01-27
KR20180075591A (ko) 2018-07-04
CN115322188A (zh) 2022-11-11
HRP20210469T1 (hr) 2021-05-14
US10851104B2 (en) 2020-12-01
CL2018001089A1 (es) 2018-08-17
DK3368534T3 (da) 2021-02-15
DK3875459T3 (da) 2024-01-29
EA201890852A1 (ru) 2018-10-31
JP7109360B2 (ja) 2022-07-29
TN2018000121A1 (en) 2019-10-04
AU2016343633A1 (en) 2018-05-10
JP2022141821A (ja) 2022-09-29
ES2972600T3 (es) 2024-06-13
EP3875459A1 (fr) 2021-09-08
PH12018500900A1 (en) 2018-11-12
RS65154B1 (sr) 2024-02-29
CN115304596A (zh) 2022-11-08
CO2018004589A2 (es) 2018-07-19
AU2016343633B2 (en) 2021-07-01
LT3875459T (lt) 2024-02-26
PL3368534T3 (pl) 2021-07-12
US10065952B2 (en) 2018-09-04
MA43116B1 (fr) 2021-04-30
US10844058B2 (en) 2020-11-24
US10851103B2 (en) 2020-12-01
MA43116A (fr) 2018-09-05
IL258732B (en) 2021-07-29
PL3875459T3 (pl) 2024-06-03
US20200339574A1 (en) 2020-10-29
EP3368534A1 (fr) 2018-09-05
HUE065406T2 (hu) 2024-05-28
MY193767A (en) 2022-10-27

Similar Documents

Publication Publication Date Title
MA56137A (fr) Sels de valbénazine et leurs polymorphes
MA46973A (fr) Polymorphes de sépiaptérine et leurs sels
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3277719T3 (da) Polypeptider
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3270930T3 (da) Præeklampsi
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
DK3286260T3 (da) Polyolefinrør
DE112015006486A5 (de) Inkubationsrinne
DK3274482T3 (da) Stenborsknop
DK3317248T3 (da) Sacubitrilcalciumsalte
DK3380465T3 (da) Diaminopyridinderivativer
DE112016005599A5 (de) Strahlungsgrill
DK3331600T3 (da) Kateter
DE112015005898A5 (de) Gurtschlossbringer
FR3034825B1 (fr) Insert taraude
DE102015206660A8 (de) Plattenaufteilanlage
MA50669A (fr) Nouveaux sels
DE112016001124A5 (de) Spannschutz
DE102015000551A8 (de) Rotationszerstäuberturbine
ES1136955Y (es) Cabezal de doble inserción
ITUA20162617A1 (it) Avvolgibile
ES1142456Y (es) Rodillo modular
CU20150017S4 (es) Vigas
CU20150012S4 (es) Tenaza de soldar